tetano
Editor, Senior Moderator
Vaccine
. 2025 Jan 30:49:126780.
doi: 10.1016/j.vaccine.2025.126780. Online ahead of print. A-910823, a squalene-based emulsion adjuvant, enhances robust and broad immune responses of quadrivalent influenza vaccine in ferrets
Masayuki Hashimoto[SUP] 1 [/SUP], Kenichiro Tsujii[SUP] 2 [/SUP], Hitomi Nakajima-Yoshida[SUP] 3 [/SUP], Nobuteru Akiyama[SUP] 4 [/SUP], Ken Yoshihara[SUP] 5 [/SUP], Keiji Dohi[SUP] 6 [/SUP], Ziwei Yin[SUP] 7 [/SUP], Aki Ejima[SUP] 8 [/SUP], Saki Yamamoto-Mizuno[SUP] 9 [/SUP], Yasushi Nojiri[SUP] 10 [/SUP], Shou Saiki[SUP] 11 [/SUP], Kaoru Baba[SUP] 12 [/SUP], Shinya Omoto[SUP] 13 [/SUP]
Affiliations
Robust and broad protective immunity is typically elicited by co-administration of an adjuvant with vaccine antigens. A-910823, a squalene-based emulsion adjuvant, has been approved in Japan. It effectively enhances the humoral and cellular immunity of S-268019-b, a recombinant COVID-19 vaccine; however, the adjuvant effects of A-910823 on other vaccines, including influenza vaccine, have not been evaluated. Here, a ferret model was employed to investigate the adjuvant effects of A-910823 when combined with split-inactivated quadrivalent influenza vaccine (QIV). We demonstrate that combination of A-910823 with QIV enhances the neutralizing antibody titer and its breadth against non-vaccine strains. Also, the protective efficacy of A-910823-adjuvanted QIV against virus challenge has been confirmed. Of note, QIV combined with A-910823 caused only minor detectable side effects, whereas a significant increase in fever was observed after two doses of mRNA-LNP in ferrets. This study provides information on the effectiveness and safety of A-910823-adjuvanted QIV and suggests the usefulness of the ferret model for evaluating vaccine-induced reactogenicity.
Keywords: A-910823; Ferrets; Quadrivalent influenza vaccine; S-268019-b.
. 2025 Jan 30:49:126780.
doi: 10.1016/j.vaccine.2025.126780. Online ahead of print. A-910823, a squalene-based emulsion adjuvant, enhances robust and broad immune responses of quadrivalent influenza vaccine in ferrets
Masayuki Hashimoto[SUP] 1 [/SUP], Kenichiro Tsujii[SUP] 2 [/SUP], Hitomi Nakajima-Yoshida[SUP] 3 [/SUP], Nobuteru Akiyama[SUP] 4 [/SUP], Ken Yoshihara[SUP] 5 [/SUP], Keiji Dohi[SUP] 6 [/SUP], Ziwei Yin[SUP] 7 [/SUP], Aki Ejima[SUP] 8 [/SUP], Saki Yamamoto-Mizuno[SUP] 9 [/SUP], Yasushi Nojiri[SUP] 10 [/SUP], Shou Saiki[SUP] 11 [/SUP], Kaoru Baba[SUP] 12 [/SUP], Shinya Omoto[SUP] 13 [/SUP]
Affiliations
- PMID: 39889536
- DOI: 10.1016/j.vaccine.2025.126780
Robust and broad protective immunity is typically elicited by co-administration of an adjuvant with vaccine antigens. A-910823, a squalene-based emulsion adjuvant, has been approved in Japan. It effectively enhances the humoral and cellular immunity of S-268019-b, a recombinant COVID-19 vaccine; however, the adjuvant effects of A-910823 on other vaccines, including influenza vaccine, have not been evaluated. Here, a ferret model was employed to investigate the adjuvant effects of A-910823 when combined with split-inactivated quadrivalent influenza vaccine (QIV). We demonstrate that combination of A-910823 with QIV enhances the neutralizing antibody titer and its breadth against non-vaccine strains. Also, the protective efficacy of A-910823-adjuvanted QIV against virus challenge has been confirmed. Of note, QIV combined with A-910823 caused only minor detectable side effects, whereas a significant increase in fever was observed after two doses of mRNA-LNP in ferrets. This study provides information on the effectiveness and safety of A-910823-adjuvanted QIV and suggests the usefulness of the ferret model for evaluating vaccine-induced reactogenicity.
Keywords: A-910823; Ferrets; Quadrivalent influenza vaccine; S-268019-b.